EGFR and non-small cell lung carcinoma: More recently, a phase II nonrandomized clinical trial demonstrated that osimertinib may be an effective treatment for previously untreated or relapsed NSCLC patients with uncommon EGFR mutations, excluding those with exon 20 insertions [17].